The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.
Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
Though Shkreli may soon slip from the public eye, separated from his Twitter account and prohibited from trading securities, pharma communicators must learn from these events.
Susan Sweeney has earned a reputation for such pragmatism and attentiveness to the things that really matter.
The CEO of Huntsworth's biggest and fastest-growing unit Huntsworth Health, which includes Nitrogen and Tonic Life, has departed after eight years.
The deal is worth roughly $2.8 billion.
Cost of throwing out expired drugs is $800 million per year; the FDA approves Gilead's new HCV drug; CDC says 1 in 10 Americans have diabetes
The relative dearth of Pharma entries, and the fact that Lions Health is very much a separate affair to the rest of the week are two factors for the Lions to keep an eye on.
Here, we profile 100 of the largest healthcare advertising agencies in North America.
Healthcare networks instigated a broad set of changes in a grand embrace of non-pharma business that diversified revenue streams and took specialist agencies out of their comfort zones.
If there is one thing to take away from the opening day at the Cannes Lions International Festival of Creativity, it is this. Find the talks that inspire you, and then find the places with AC.
A public health campaign developed by McCann Health India for children in Afghanistan was the big winner in 2017.
In the Lions Health pharma shortlist, released Saturday morning, five branded campaign made it through the judging process for the branded prescription categories.
Sanofi to boost investment in biologics R&D; Sage's awareness campaign criticized; PatientsLikeMe poll finds 95% of patients want some costs of drugs covered
It's never been easy for pharmaceutical companies or healthcare brands to authentically engage with patients or with doctors.
The executive director of oncology marketing is fascinated by the resilience of the human body.
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.
Harvard Pilgrim signs two outcomes contracts with AstraZeneca; lobbyists fight over drug-pricing proposals; docs say no to adult ADHD screening test
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.
Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.
After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.
The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.
Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.
The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.
Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.
Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.
The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.